



Prana Biotechnology admitted to S&P/ASX 300 Index

MELBOURNE, March 11, 2014: Prana Biotechnology (ASX:PBT) is pleased to announce that effective March 21 it is a constituent stock of the S&P/ASX 300 Index after a quarterly review by Dow Jones.

The S&P/ASX 300 Index is adjusted every quarter to reflect Australia's top 300 stocks based on market capitalisation. As an important benchmark for investors, entrance to the index exposes Prana to a wider range of investors seeking greater size and liquidity.

In the past three months, Prana's share price has increased 93.6% to \$511.95M at close of trading, March 6, 2014.

As a member of the ASX 300, Prana will have exposure to new investors, and provides opportunities for institutional investors tied to investing in certain indices.

The company is expecting the release of the results of a Phase 2 Alzheimer's Disease trial later this month.

-ENDS-

Contacts:

Investor Relations

Rebecca Wilson

T: +61 3 9866 4722

E: rwilson@bucanwe.com.au

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the



exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factors including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.